Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
801-820 of 936 trials

Antibiotics in Children with Brain Tumors

We are studying how different antibiotics move into the cerebrospinal fluid of children with malignant brain tumors. This research may help improve treatment for infections in these patients.

Brain Tumors>2 yearsSafety phase (I)No PlaceboStandard MedicinesInfectious DiseasesOncologyPediatrics

Blood Cancers: Sonrotoclax Safety Study

We are investigating new dosing schedules for Sonrotoclax in adults with blood cancers. The study aims to understand the safety and tolerability of this treatment approach.

Chronic Lymphocytic LeukemiaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

V540C Vaccine Study in Healthy Adults

We are investigating the V540C vaccine to see how it works in healthy adults. This study aims to assess its safety and immune response.

Human Papilloma Virus Infection1-2 yearsSafety phase (I)Infectious DiseasesOncology

HIV Treatment: Venetoclax Study

We are testing the safety of a medication called venetoclax in people living with HIV who are on antiretroviral therapy. The aim is to see if it can help reduce the size of the HIV reservoir in the body.

HIV-1 Disease1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyInfectious Diseases

SDL-M1 Nanoparticles: Safety Study

We are investigating the safety and tolerability of SDL-M1 nanoparticles in healthy volunteers. This study aims to gather important information before testing in patients.

Intrahepatic CholestasisSafety phase (I)Hepatology

Virus-Specific T-Cell Therapy for Resistant Viral Infections Post-Stem Cell Transplant

We are studying the safety of using specially selected T-cells to treat young patients with viral infections like Adenovirus and Cytomegalovirus after a stem cell transplant. The trial also aims to see how well this treatment controls symptoms related to these infections.

Graft Infection1-2 yearsSafety phase (I)No PlaceboHematologyInfectious Diseases

Autoimmune Diseases: VIS171 Treatment

We are testing a new treatment called VIS171 for individuals with autoimmune diseases. The study aims to evaluate its safety and how the body reacts to it.

Alopecia AreataSystemic Lupus ErythematosusImmune-Mediated Focal Segmental Glomerulosclerosis1-2 yearsSafety phase (I)Infectious DiseasesInternal Medicine

Colorectal Cancer: Galunisertib and Capecitabine Study

We are investigating a new drug combination for patients with advanced colorectal cancer that hasn't responded to chemotherapy. The goal is to learn more about its safety and effectiveness in treating this condition.

Metastatic Colorectal CancerSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Advanced Solid Tumors: PM534 Treatment

We are testing a new drug called PM534 for patients with advanced solid tumors. The goal is to learn about its safety and how it may help in treating this condition.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Systemic Lupus Erythematosus: AZD5492 Study

We are investigating a new medication for adults with systemic lupus erythematosus or idiopathic inflammatory myopathies. The study focuses on its safety and how the body processes the drug.

Systemic Lupus ErythematosusIdiopathic Inflammatory Myopathy>2 yearsSafety phase (I)Rheumatology

Dry Age-Related Macular Degeneration: PST-611 Treatment

We are testing the safety and tolerability of PST-611 in individuals with dry age-related macular degeneration. This study aims to understand how well the treatment is accepted by patients.

Dry Age-Related Macular Degeneration6-12 monthsSafety phase (I)Ophthalmology

Rheumatoid Arthritis: CLN-978 Treatment

We are testing a new treatment called CLN-978 for patients with rheumatoid arthritis who haven't found relief from existing medications. The goal is to see if it can help manage their symptoms better.

Rheumatoid Arthritis>2 yearsSafety phase (I)Rheumatology

LY4057996: A Study in Diabetes

We are testing a new treatment in healthy participants and those with type 1 and type 2 diabetes. The goal is to learn more about its effects and safety in these different groups.

Healthy ParticipantsType 1 DiabetesType 2 DiabetesSafety phase (I)DiabetologyEndocrinology

Advanced Cancers: Testing IPH4502

We are investigating the safety and effects of a new drug, IPH4502, in people with advanced cancers. This study aims to understand how the drug works in humans for the first time.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Pasireotide: Injection Methods Study

We are investigating how well pasireotide is absorbed when given under the skin with a pen versus a syringe in healthy volunteers. This research may help improve how this medication is administered in the future.

Postprandial HypoglycemiaSafety phase (I)EndocrinologyInternal Medicine

Ovarian Cancer: PARP Inhibitor with Cisplatin and Heat Therapy

We are studying a new treatment approach for ovarian cancer that combines a PARP inhibitor with cisplatin and heat during surgery. This trial aims to see if this combination improves outcomes for patients.

Fallopian Tube CancerOvarian CancerExtraovarian Cancer>2 yearsSafety phase (I)Efficacy phase (II)Gynecology and ObstetricsOncology

New T Cell Therapy for Pediatric Blood Cancers

We are testing a modified T cell treatment for children with relapsed or hard-to-treat B-cell leukemia and lymphoma. The study aims to evaluate safety and effectiveness in helping these patients achieve remission.

Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia and Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncologyPediatrics

Advanced Solid Tumors: Testing IPN01195

We are studying a new medicine called IPN01195 to see how safe it is and what the best dose is for adults with advanced solid tumors. This trial aims to understand its effects on tumor activity and how it works in the body.

Advanced Solid Tumour3-6 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementOncology

HER2 Cancers: IAM1363 Treatment Study

We are testing IAM1363 in patients with HER2-positive cancers to see how safe it is and to find the right dosage. This study aims to gather important information for future treatments.

HER2 Gene Amplification1-2 yearsSafety phase (I)Oncology

Blood Cancers: IDP-121 Treatment Study

We are testing a new medication, IDP-121, for patients with relapsed or refractory blood cancers like multiple myeloma and B-cell lymphoma. The goal is to find the best dose and see how well it helps improve patient outcomes.

Chronic Lymphocytic Leukemia (CLL)B-cell LymphomasMultiple Myeloma (MM)6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology